Suven Pharmaceuticals Limited (SUVENPHAR.NS)
INR 1222.2
(-1.95%)
INR 1222.2
(-1.95%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 3.52 Billion | 4.5 Billion | 3.3 Billion | 3.83 Billion | 4.15 Billion | 504.04 Million |
| Net Income | 3 Billion | 5.59 Billion | 6.67 Billion | 4.67 Billion | 4.04 Billion | 1.57 Billion |
| Depreciation & Amortization | 545.95 Million | 464.59 Million | 382.55 Million | 312.2 Million | 236.82 Million | 114.96 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 19.66 Million | - | - | - | - | - |
| Change in working capital | 474.11 Million | 56.35 Million | -1.93 Billion | -112.81 Million | 452.27 Million | -883.26 Million |
| Other non-cash items | 292.31 Million | -1.6 Billion | -1.81 Billion | -1.04 Billion | -574.72 Million | -306.32 Million |
| Investing Cash Flow | -3.64 Billion | -1.94 Billion | -1.36 Billion | -3.11 Billion | -4.21 Billion | -654.79 Million |
| Investments in PPE | -517.86 Million | -2.85 Billion | -751.86 Million | -1.1 Billion | -994.14 Million | -567.85 Million |
| Acquisitions | - | 720 Thousand | 6000.00 | 336 Thousand | 1.34 Million | - |
| Investment purchases | -3.13 Billion | -44 Thousand | -3 Billion | -2 Billion | -3.25 Billion | -68.97 Million |
| Sales/Maturities of investments | 11.1 Million | 844.78 Million | 2.44 Billion | -336 Thousand | 3.25 Billion | - |
| Other Investing Activities | 422 Thousand | 63.83 Million | -48.43 Million | 309 Thousand | -3.22 Billion | -17.96 Million |
| Financing Cash Flow | -63.51 Million | -2.35 Billion | -1.56 Billion | -765.52 Million | 63.67 Million | 259.77 Million |
| Debt repayment | -63.51 Million | -263.68 Million | -481.94 Million | -415.33 Million | -1.01 Billion | -517.83 Million |
| Dividends payments | - | -2.03 Billion | -1.01 Billion | -254.56 Million | -767.22 Million | -230.16 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -344.95 Million | -58.11 Million | -63.91 Million | -95.62 Million | 1.84 Billion | 1 Billion |
| Accounts receivables | -228.02 Million | 1.24 Billion | -1.36 Billion | 133.6 Million | 346.18 Million | -2.03 Billion |
| Accounts payables | -281.73 Million | -407.25 Million | 232.03 Million | 119.45 Million | 171.28 Million | 98.53 Million |
| Inventory | 816.14 Million | -293.93 Million | -823.36 Million | -262.08 Million | -177.73 Million | -170.89 Million |
| Other working capital | 167.73 Million | -487.1 Million | 12.55 Million | -103.79 Million | 112.54 Million | 1.22 Billion |
| Cash at beginning of period | 658.6 Million | 445.63 Million | 71.82 Million | 116.95 Million | 109.02 Million | - |
| Cash at end of period | 504.98 Million | 648.02 Million | 445.63 Million | 71.82 Million | 116.95 Million | 109.02 Million |
| Capital Expenditure | -517.86 Million | -2.85 Billion | -751.86 Million | -1.1 Billion | -994.14 Million | -567.85 Million |
| Effect of forex changes on cash | 9000.00 | - | 4000.00 | 3000.00 | 6000.00 | - |
| Net cash flow / Change in cash | -153.61 Million | 202.39 Million | 373.81 Million | -45.13 Million | 7.92 Million | 109.02 Million |
| Free Cash Flow | 3.01 Billion | 1.65 Billion | 2.54 Billion | 2.72 Billion | 3.16 Billion | -63.81 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 607.7 Million | 3 Billion | 533.73 Million | 467.53 Million | 795.64 Million | 1.2 Billion |
| Depreciation & Amortization | - | 545.95 Million | - | 127.51 Million | 118.91 Million | 125.41 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 19.66 Million | 19.94 Million | - | - | - |
| Change in working capital | - | 474.11 Million | - | - | - | - |
| Other non-cash items | -607.7 Million | 292.31 Million | -553.67 Million | -467.53 Million | -795.64 Million | -1.2 Billion |
| Investing Cash Flow | - | -3.64 Billion | - | - | - | - |
| Investments in PPE | - | -517.86 Million | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -3.13 Billion | - | - | - | - |
| Sales/Maturities of investments | - | 11.1 Million | - | - | - | - |
| Other Investing Activities | - | 422 Thousand | - | - | - | - |
| Financing Cash Flow | - | -63.51 Million | - | - | - | - |
| Debt repayment | - | -63.51 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | -344.95 Million | - | - | - | - |
| Accounts receivables | - | -228.02 Million | - | - | - | - |
| Accounts payables | - | -281.73 Million | - | - | - | - |
| Inventory | - | 816.14 Million | - | - | - | - |
| Other working capital | - | 167.73 Million | - | - | - | - |
| Cash at beginning of period | - | 658.6 Million | - | 608.05 Million | 370.22 Million | 658.6 Million |
| Cash at end of period | - | 504.98 Million | - | 863.09 Million | 608.05 Million | 909.42 Million |
| Capital Expenditure | - | -517.86 Million | - | - | - | - |
| Effect of forex changes on cash | - | 9000.00 | - | - | - | - |
| Net cash flow / Change in cash | - | -153.61 Million | - | 255.03 Million | 237.83 Million | 250.82 Million |
| Free Cash Flow | - | 3.01 Billion | - | 255.03 Million | 237.83 Million | 250.82 Million |
NLLSF
PLNK
BGOPF
AKASH
XAIR
688335